However, in glioblastoma cells, loss of PARP1 expression by CRISPR-KO did not sensitize MSH6-mutant tumor cells to the alkylating agent temozolomide (TMZ), suggesting a more complicated role for PARP in response to alkylating agents [382]. This evidence concerns the gene PARP1 and neoplasm.